SCHEMBL10170

SCHEMBL10170

CCCC(=O)NC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 4/20 0.52
HDAC3 O15379 3/20 0.52
HDAC1 Q13547 3/20 0.52
HDAC8 Q9BY41 3/20 0.52
HDAC6 Q9UBN7 1/20 0.52
ALDH1A1 P00352 2/20 0.50
CTSD P07339 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.46
HPGD P15428 1/20 0.43
CASP2 P42575 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
FFAR3 O14843 2/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
PRSS1 P07477 1/20 0.37
CTSG P08311 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19171550 0.86 SMN1; SMN2 (0.50) HDAC2ALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL9462903 0.85 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HPGDCES2CES1
SCHEMBL9462966 0.83 ALDH1A1 (0.61) ALDH1A1CES2CES1TSHR
SCHEMBL3318249 0.82 SMN1; SMN2 (0.44) HDAC2ALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL24507360 0.81 HSP90AA1 (0.59) ALDH1A1CES2CES1TSHR
SCHEMBL13701707 0.81 HSP90AA1 (0.59) ALDH1A1CES2CES1TSHR
SCHEMBL12920382 0.81 HSP90AA1 (0.59) ALDH1A1CES2CES1TSHR
SCHEMBL12057493 0.81 HSP90AA1 (0.59) ALDH1A1CES2CES1TSHR
SCHEMBL23378025 0.81 HSP90AA1 (0.59) ALDH1A1CES2CES1TSHR
Ammonia Solution, Strong SCHEMBL28073881 0.81 ALDH1A1 (0.59) ALDH1A1CES2CES1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112870375-A Multi-channel bionic nano carrier for cutting off tumor energy supply and preparation method and application thereof 西安交通大学 2021-06-01 CN claimed
US-4026926-A COMPLEX OF SULFUR TRIOXIDE WITH A SECONDARY AMIDE TOHO BESLON KABUSHIKI KAISHA (JA) 1977-05-31 US claimed
US-20240066141-A1 LINKERS, CONJUGATES AND APPLICATIONS THEREOF GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) 2024-02-29 US disclosed
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-01-02 US disclosed
US-11826432-B2 Linkers, conjugates and applications thereof GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) 2023-11-28 US disclosed
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-11-09 US disclosed
US-11787779-B2 Sulfone pyridine alkyl amide-substituted heteroaryl compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-17 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-07-25 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
WO-2000000499-A1 METHOD FOR PREPARING OLIGONUCLEOTIDES WITH BORANOPHOSPHATE LINKAGES ISIS PHARMACEUTICALS, INC. (US) 2000-01-06 WO disclosed
EP-0847988-A1 Process for the preparation of N-hydrocarbyl-substituted amides The Lubrizol Corporation (US) 1998-06-17 EP disclosed
EP-0827507-A1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1998-03-11 EP disclosed
US-5712413-A Process for the preparation of N-hydrocarbyl-substituted amides such as tert-butylacrylamide via the Ritter reaction using solid heteropolyacid catalysts THE LUBRIZOL CORPORATION (US) 1998-01-27 US disclosed
CN-1033584-C Benzo-fused lactams that promote release of growth hormone MERCK & CO INC (US) 1996-12-18 CN disclosed
WO-1996031527-A1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) 1996-10-10 WO disclosed
CN-1076690-A SULFONAMIDOCARBOXAMIDES HOFFMANN LA ROCHE (CH) 1993-09-29 CN disclosed
CN-1066070-A Promote the new benzo-fused lactams that tethelin discharges MERCK & CO INC (US) 1992-11-11 CN disclosed
US-4026926-A COMPLEX OF SULFUR TRIOXIDE WITH A SECONDARY AMIDE TOHO BESLON KABUSHIKI KAISHA (JA) 1977-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 HDAC2 4547/4885HDAC3 4815/4885HDAC1 4619/4885
US-11826432-B2 Linkers, conjugates and applications thereof CD44, EPCAM, MSN HDAC2 3384/4885HDAC3 1468/4885HDAC1 2616/4885
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders CFD, TFPI, CFH HDAC2 1907/4885HDAC3 1352/4885HDAC1 1872/4885
US-11787779-B2 Sulfone pyridine alkyl amide-substituted heteroaryl compounds TYK2, JAK3, JAK2 HDAC2 549/4885HDAC3 515/4885HDAC1 875/4885
US-20240066141-A1 LINKERS, CONJUGATES AND APPLICATIONS THEREOF CD44, EPCAM, MSN HDAC2 3384/4885HDAC3 1468/4885HDAC1 2616/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI HDAC2 4229/4885HDAC3 4564/4885HDAC1 4175/4885
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH HDAC2 1907/4885HDAC3 1352/4885HDAC1 1872/4885
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use LRRK2, ADRM1, CRBN HDAC2 2135/4885HDAC3 3468/4885HDAC1 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.